Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow COAG by emailGet an email when COAG pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about COAG, unsubscribe in one click. Privacy
📣 What COAG Says Is Next
second half of 2026 · “The Company plans to initiate first-in-human studies in the second half of 2026 with initial clinical data mid-2027.”
Company press release, Aug 11, 2026 · SEC filing
late 2026 · “The Company expects to report additional data from the trial in late 2026 or early 2027.”
Company press release, Aug 11, 2026 · SEC filing
late 2026 · “The Company expects to report data from the ongoing Phase 2 trial in late 2026 or early 2027.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full COAG picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COAG and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.